Teligent Research and Development Expenses 2012-2021 | TLGT
Teligent research and development expenses from 2012 to 2021. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
Teligent Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2020 | $8 |
| 2019 | $11 |
| 2018 | $14 |
| 2017 | $19 |
| 2016 | $17 |
| 2015 | $13 |
| 2014 | $7 |
| 2013 | $3 |
| 2012 | $3 |
| 2011 | $2 |
|
Teligent Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2021-06-30 | $2 |
| 2021-03-31 | $1 |
| 2020-12-31 | $2 |
| 2020-09-30 | $2 |
| 2020-06-30 | $2 |
| 2020-03-31 | $2 |
| 2019-12-31 | $3 |
| 2019-09-30 | $2 |
| 2019-06-30 | $3 |
| 2019-03-31 | $3 |
| 2018-12-31 | $4 |
| 2018-09-30 | $3 |
| 2018-06-30 | $4 |
| 2018-03-31 | $3 |
| 2017-12-31 | $6 |
| 2017-09-30 | $5 |
| 2017-06-30 | $5 |
| 2017-03-31 | $4 |
| 2016-12-31 | $5 |
| 2016-09-30 | $4 |
| 2016-06-30 | $5 |
| 2016-03-31 | $4 |
| 2015-12-31 | $4 |
| 2015-09-30 | $3 |
| 2015-06-30 | $3 |
| 2015-03-31 | $3 |
| 2014-12-31 | $2 |
| 2014-09-30 | $2 |
| 2014-06-30 | $2 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $0 |
| 2011-12-31 | $1 |
| 2011-09-30 | $0 |
| 2011-06-30 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |